Table 2.
Preoperative Unified Parkinson's Disease Rating Scale scores and response to l-dopa according to genetic subgroup
| Mean ± SD | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UPDRS-II | UPDRS-III | UPDRS-IV | |||||||||||||||||||||||||||
| Genetic test results | Duration of PD at DBS assessment, y | LED, mg | UPDRS-I | Off meds | On meds | Off meds | On meds | Percentage improvement in score with l-dopa | Dyskinesia score | Off meds score | |||||||||||||||||||
| Parkin (compound heterozygotes/homozygotes; N = 5) | 25.2 ± 12.8 | 960 ± 611 | 1.7 ± 2.1 | 24.3 ± 4.0 | 6 ± 6.2 | 57.0 ± 11.2 | 21.0 ± 6.4 | 61.0 ± 18.3 | 5.3 ± 3.9 | 3.5 ± 1.3 | |||||||||||||||||||
| GBA (confirmed mutation; N = 16) | 11.2 ± 5.0 | 1143 ± 540 | 1.5 ± 1.5 | 23.1 ± 12.3 | 10.9 ± 11.8 | 51.3 ± 14.0 | 18.0 ± 15.4 | 66.9 ± 18.6 | 3.0 ± 2.7 | 4.6 ± 2.1 | |||||||||||||||||||
| LRRK2 (N = 5) | 12.1 ± 1.8 | 1317 ± 803 | 1.2 ± 1.1 | 26.8 ± 7.9 | 4.5 ± 4.4 | 65.4 ± 14.9 | 10.8 ± 5.1 | 84.9 ± 5.5 | 4.2 ± 3.1 | 5.2 ± 1.3 | |||||||||||||||||||
| No mutation found (N = 67) | 15.1 ± 5.5 | 1259 ± 559 | 2.0 ± 1.6 | 22.9 ± 7.9 | 8.0 ± 7.2 | 47.4 ± 14.7 | 15.6 ± 11.3 | 68.5 ± 19.3 | 3.0 ± 2.2 | 4.5 ± 1.3 | |||||||||||||||||||
SD, standard deviation; UPDRS-I through UPDRS-IV, Unified Parkinson's Disease Rating Scale parts 1 (nonmotor activities of daily living), 2 (motor activities of daily living), 3 (motor examination), and 4 (motor complications), respectively; DBS, deep brain stimulation; meds, medication; LED, l-dopa equivalent dose; GBA, glucosidase beta acid; LRRK2, leucine-rich repeat kinase 2.